Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection
Status:
Recruiting
Trial end date:
2021-03-25
Target enrollment:
Participant gender:
Summary
This is an open-label Phase I study, four dose escalation groups, to evaluate the safety of
CD24-exosomes in patients with moderate/severe COVID-19 disease.
Patients with moderate/severe COVID-19 infection and factors predictive of a cytokine storm
are recruited from the Corona department of the Tel Aviv Sourasky Medical Center (TASMC), who
have provided informed consent are being recruited in four dose groups who will receive the
exosome treatment as an add-on treatment to standard treatment.